超声心动图参数及HSP70基因多态性与老年慢性心力衰竭预后的相关性分析

摘要/Abstract

摘要： 目的：分析超声心动图参数、热休克蛋白70（HSP70）基因多态性与老年慢性心力衰竭患者预后的相关性。方法：选取2019年10月至2021年10月于我院治疗的老年慢性心力衰竭患者142例作为研究对象，对其进行1年随访观察，用是否发生心血管事件评估其预后情况，将其分为预后不良组（32例）、预后良好组（110例）。收集患者出院前超声心动图检测参数，采用聚合酶链反应（PCR）结合限制性内切酶分析检测HSP70-1基因+190G/C、HSP70-2基因+1267A/C、HSP70-hom基因+2437T/C多态性，结合患者临床人口学与病理资料，分析两组患者超声心动图参数及HSP70基因多态性差异。采用二元Logistic回归分析老年慢性心力衰竭预后与超声心动图参数及HSP70基因多态性的相关性，建立ROC曲线评估超声心动图参数及HSP70基因多态性预测预后不良的价值。结果：与预后良好组患者相比，预后不良组患者超声心动图参数左心室舒张末期直径（LVEDD）、左心室收缩末期直径（LVESD）均更高（P<0.05），左心室射血分数（LVEF）更低（P<0.05）。与预后良好组患者相比，预后不良组患者HSP70-2基因+1267A/C基因型、等位基因差异有统计学意义（P<0.05）。Logistic回归分析显示年龄、LVEDD、LVEF、HSP70-2基因+1267A/C多态性是预后不良的影响因素（P<0.05）。LVEDD、LVEF、HSP70-2基因+1267A/C多态性单独、联合预测预后不良曲线下面积分别为0.728、0.852、0.624、0.985。结论：LVEDD、LVEF、HSP70-2基因+1267A/C多态性是老年慢性心力衰竭患者预后的影响因素，LVEDD升高，LVEF降低以及GG基因型均可增加老年慢性心力衰竭预后不良风险，三者联合时预测预后不良效能更高。

关键词: font-size:medium, ">超声心动图；热休克蛋白70；慢性心力衰竭；老年；预后

Abstract: Objective：To analyze the correlation between echocardiography parameters， heat shock protein 70(HSP70) gene polymorphism and the prognosis of elderly patients with chronic heart failure.Methods：142 elderly patients with chronic heart failure treated in our hospital from October 2019 to October 2021 were selected as the research objects， and were followed up for one year. The prognosis was evaluated by whether cardiovascular events occurred， and the patients were divided into the poor prognosis group (32 cases) and the good prognosis group (110 cases). The echocardiographic parameters of the patients were collected before discharge， and the polymorphisms of HSP70-1 gene+190G/C， HSP70-2 gene+1267A/C， HSP70-hom gene+2437T/C were detected by polymerase chain reaction (PCR) and restriction endonuclease analysis. The differences of echocardiographic parameters and HSP70 gene polymorphisms between the two groups were analyzed based on the clinical demographic and pathological data of the patients. Binary logistic regression analysis was used to analyze the correlation between the prognosis of elderly chronic heart failure and echocardiography parameters and HSP70 gene polymorphism. Results：Compared with the good prognosis group， LVEDD and LVESD of patients in the poor prognosis group were higher， and LVEF was lower (P<0.05). Compared with the good prognosis group， HSP70-2 gene+1267A/C genotype and allele of patients in the poor prognosis group were statistically significant difference (P<0.05). Logistic regression analysis showed that age， LVEDD， LVEF， HSP70-2 gene+1267A/C polymorphism were the factors influencing poor prognosis (P<0.05). The areas under the curve of LVEDD， LVEF and HSP70-2 genes +1267A/C polymorphism alone and jointly predicfing poor prognosis were 0.728， 0.852， 0.624 and 0.985 respective.Conclusion：LVEDD， LVEF， HSP70-2 gene+1267A/C polymorphisms are factors influencing the prognosis of elderly patients with chronic heart failure. Elevated LVEDD， decreased LVEF， and GG genotype can increase the risk of poor prognosis of elderly patients with chronic heart failure. The combination of the three are more effective in predicting poor prognosis.

Key words: font-size:medium, ">Echocardiography； Heat shock protein 70； Chronic heart failure； Old age；Prognosis

中图分类号:

刘力华, 刘娟. 超声心动图参数及HSP70基因多态性与老年慢性心力衰竭预后的相关性分析[J]. 中国医药导刊, 2023, 25(1): 45-50.

LIU Lihua, LIU Juan. Correlation Analysis of Echocardiographic Parameters and HSP70 Gene Polymorphism with the Prognosis of Chronic Heart Failure in the Elderly[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(1): 45-50.

参考文献

[1]Beldhuis IE，Lam CSP，Testani JM，et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease[J]. Circulation，2022，145(9)：693-712.
     [2]van der Aart-van der Beek AB， de Boer RA， Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use[J]. Nat Rev Nephrol， 2022， 18(5)：294-306.
     [3]Abdin A， Anker SD， Butler J， et al. ‘Time is prognosis’ in heart failure： time-to-treatment initiation as a modifiable risk factor[J]. ESC Heart Fail，2021，8(6)：4444-4453.
     [4]孙瑞华，都渝，鲍巧玲，等. 热休克蛋白干预脑缺血缺氧模型大鼠神经功能及脑组织中血红素加氧酶1蛋白的表达[J]. 中国组织工程研究， 2023， 27(14)：2146-2151.
     [5]邓爽，蒲锐，陈子扬，等.运动预适应干预压力超负荷心肌重构模型小鼠的心肌功能及细胞凋亡[J].中国组织工程研究， 2022，26(5)：717-723.
     [6]宋势波，欧阳斯华，李艺玲.超声心动图联合血清β2-微球蛋白、同型半胱氨酸评估扩张型心肌病患者心力衰竭风险的价值[J]. 临床超声医学杂志，2022，24(6)：465-468.
     [7]中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志，2018， 46(10)：760-789.
     [8]Nicholls M.Telemedicine for chronic heart failure patients[J].Eur Heart J，2021，42(46)：4713-4715.
     [9]Salama S， Choudhury A， Kane SP. Chronic heart failure： a pharmacologic review[J]. Orthop Nurs，2022，41(5)：363-368.
     [10]Kang C，Lamb YN.Vericiguat：a review in chronic heart failure with reduced ejection fraction[J]. Am J Cardiovasc Drugs， 2022，22(4)：451-459.
     [11]全强，黄冬花，陈秋月，等.不同类型心力衰竭患者超声心动图参数、NT-proBNP及其临床意义[J]. 中南医学科学杂志，2022，50(3)：449-451，465.
     [12]陈霞.超声心动图参数联合血清可溶性基质裂解素2水平对老年慢性心力衰竭患者预后不良的预测价值[J].心脑血管病防治，2022，22(2)：37-40，45.
     [13]田倪妮，魏玲，李宏键，等.心肌热休克蛋白70在慢性心力衰竭患者中的表达[J].心脏杂志，2015，27(3)：314-317.
     [14]吕蓓丽，张晓枫，蔡礼鸣，等.HSP70基因多态性与重症肺炎临床转归的关系[J].中华医院感染学杂志，2021，31(14)：2139-2143.
     [15]刘锋瑞，高红艳，王丽，等.热休克蛋白70基因多态性与慢性心力衰竭患者预后的相关性研究[J].临床心血管病杂志，2018，34(6)：572-577.

快速检索引用检索图表检索高级检索